These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28549443)

  • 1. Quantitative analysis of cryptic splicing associated with TDP-43 depletion.
    Humphrey J; Emmett W; Fratta P; Isaacs AM; Plagnol V
    BMC Med Genomics; 2017 May; 10(1):38. PubMed ID: 28549443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.
    Ling JP; Pletnikova O; Troncoso JC; Wong PC
    Science; 2015 Aug; 349(6248):650-5. PubMed ID: 26250685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TDP-43 and other hnRNPs regulate cryptic exon inclusion of a key ALS/FTD risk gene, UNC13A.
    Koike Y; Pickles S; Estades Ayuso V; Jansen-West K; Qi YA; Li Z; Daughrity LM; Yue M; Zhang YJ; Cook CN; Dickson DW; Ward M; Petrucelli L; Prudencio M
    PLoS Biol; 2023 Mar; 21(3):e3002028. PubMed ID: 36930682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue.
    Cao MC; Ryan B; Wu J; Curtis MA; Faull RLM; Dragunow M; Scotter EL
    Neurobiol Dis; 2023 Sep; 185():106245. PubMed ID: 37527763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers.
    Akiyama T; Koike Y; Petrucelli L; Gitler AD
    Clin Transl Med; 2022 May; 12(5):e818. PubMed ID: 35567447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.
    Ma XR; Prudencio M; Koike Y; Vatsavayai SC; Kim G; Harbinski F; Briner A; Rodriguez CM; Guo C; Akiyama T; Schmidt HB; Cummings BB; Wyatt DW; Kurylo K; Miller G; Mekhoubad S; Sallee N; Mekonnen G; Ganser L; Rubien JD; Jansen-West K; Cook CN; Pickles S; Oskarsson B; Graff-Radford NR; Boeve BF; Knopman DS; Petersen RC; Dickson DW; Shorter J; Myong S; Green EM; Seeley WW; Petrucelli L; Gitler AD
    Nature; 2022 Mar; 603(7899):124-130. PubMed ID: 35197626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptic exon detection and transcriptomic changes revealed in single-nuclei RNA sequencing of C9ORF72 patients spanning the ALS-FTD spectrum.
    Gittings LM; Alsop EB; Antone J; Singer M; Whitsett TG; Sattler R; Van Keuren-Jensen K
    Acta Neuropathol; 2023 Sep; 146(3):433-450. PubMed ID: 37466726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD.
    Seddighi S; Qi YA; Brown AL; Wilkins OG; Bereda C; Belair C; Zhang YJ; Prudencio M; Keuss MJ; Khandeshi A; Pickles S; Kargbo-Hill SE; Hawrot J; Ramos DM; Yuan H; Roberts J; Sacramento EK; Shah SI; Nalls MA; Colón-Mercado JM; Reyes JF; Ryan VH; Nelson MP; Cook CN; Li Z; Screven L; Kwan JY; Mehta PR; Zanovello M; Hallegger M; Shantaraman A; Ping L; Koike Y; Oskarsson B; Staff NP; Duong DM; Ahmed A; Secrier M; Ule J; Jacobson S; Reich DS; Rohrer JD; Malaspina A; Dickson DW; Glass JD; Ori A; Seyfried NT; Maragkakis M; Petrucelli L; Fratta P; Ward ME
    Sci Transl Med; 2024 Feb; 16(734):eadg7162. PubMed ID: 38277467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models.
    Tan Q; Yalamanchili HK; Park J; De Maio A; Lu HC; Wan YW; White JJ; Bondar VV; Sayegh LS; Liu X; Gao Y; Sillitoe RV; Orr HT; Liu Z; Zoghbi HY
    Hum Mol Genet; 2016 Dec; 25(23):5083-5093. PubMed ID: 28007900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.
    Lagier-Tourenne C; Polymenidou M; Hutt KR; Vu AQ; Baughn M; Huelga SC; Clutario KM; Ling SC; Liang TY; Mazur C; Wancewicz E; Kim AS; Watt A; Freier S; Hicks GG; Donohue JP; Shiue L; Bennett CF; Ravits J; Cleveland DW; Yeo GW
    Nat Neurosci; 2012 Nov; 15(11):1488-97. PubMed ID: 23023293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
    Hayes LR; Kalab P
    Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease.
    Agra Almeida Quadros AR; Li Z; Wang X; Ndayambaje IS; Aryal S; Ramesh N; Nolan M; Jayakumar R; Han Y; Stillman H; Aguilar C; Wheeler HJ; Connors T; Lopez-Erauskin J; Baughn MW; Melamed Z; Beccari MS; Olmedo Martínez L; Canori M; Lee CZ; Moran L; Draper I; Kopin AS; Oakley DH; Dickson DW; Cleveland DW; Hyman BT; Das S; Ertekin-Taner N; Lagier-Tourenne C
    Acta Neuropathol; 2024 Jan; 147(1):9. PubMed ID: 38175301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43.
    Sun M; Bell W; LaClair KD; Ling JP; Han H; Kageyama Y; Pletnikova O; Troncoso JC; Wong PC; Chen LL
    Acta Neuropathol; 2017 Jun; 133(6):923-931. PubMed ID: 28332094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.
    Brown AL; Wilkins OG; Keuss MJ; Hill SE; Zanovello M; Lee WC; Bampton A; Lee FCY; Masino L; Qi YA; Bryce-Smith S; Gatt A; Hallegger M; Fagegaltier D; Phatnani H; ; Newcombe J; Gustavsson EK; Seddighi S; Reyes JF; Coon SL; Ramos D; Schiavo G; Fisher EMC; Raj T; Secrier M; Lashley T; Ule J; Buratti E; Humphrey J; Ward ME; Fratta P
    Nature; 2022 Mar; 603(7899):131-137. PubMed ID: 35197628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptic inclusions UNCover losses driving neurodegeneration.
    Bademosi AT; Walker AK
    Trends Genet; 2022 Sep; 38(9):889-891. PubMed ID: 35773026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The era of cryptic exons: implications for ALS-FTD.
    Mehta PR; Brown AL; Ward ME; Fratta P
    Mol Neurodegener; 2023 Mar; 18(1):16. PubMed ID: 36922834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.
    Irwin KE; Jasin P; Braunstein KE; Sinha IR; Garret MA; Bowden KD; Chang K; Troncoso JC; Moghekar A; Oh ES; Raitcheva D; Bartlett D; Miller T; Berry JD; Traynor BJ; Ling JP; Wong PC
    Nat Med; 2024 Feb; 30(2):382-393. PubMed ID: 38278991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
    Jovičić A; Paul JW; Gitler AD
    J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation of the focus toward excellence in translational science: comment on "TDP-43 Repression of Nonconserved Cryptic Exons is Compromised in ALS-FTD".
    Pochet R; Nicaise C; Mitrečić D
    Croat Med J; 2015 Oct; 56(5):493-5. PubMed ID: 26526887
    [No Abstract]   [Full Text] [Related]  

  • 20. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.
    Sidibé H; Khalfallah Y; Xiao S; Gómez NB; Fakim H; Tank EMH; Di Tomasso G; Bareke E; Aulas A; McKeever PM; Melamed Z; Destroimaisons L; Deshaies JE; Zinman L; Parker JA; Legault P; Tétreault M; Barmada SJ; Robertson J; Vande Velde C
    Brain; 2021 Dec; 144(11):3461-3476. PubMed ID: 34115105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.